JNJ
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals
Johnson & Johnson
$221.32
-1.19 (-0.53%)
JNJ News30 articles
Wall Street Hits New Highs on Tech Surge; Dow Flat Despite Jobs Data
The S&P 500 and Nasdaq hit record highs Friday, driven by AI and semiconductor stocks, while the Dow Jones barely budged after a solid jobs report.
Dow Rises as Coca-Cola Gains Offset AI-Led Tech Selloff
The Dow Jones Industrial Average edged higher Tuesday as Coca-Cola's earnings boosted blue chips, while the Nasdaq slumped on AI sector concerns and rising oil prices.
Intuitive Surgical Shares Surge on Upgraded Forecast, Robust da Vinci Sales
Intuitive Surgical shares climbed to $482.22 after the company raised its 2026 growth outlook and reported a 23% revenue jump to $2.77 billion in Q1, driven by strong da Vinci system placements.
Tech Stocks Drive Market Gains Amid Ceasefire Relief and Earnings Strength
U.S. stocks climbed Wednesday, with the Nasdaq leading gains as technology shares rallied following an extended Iran ceasefire and a wave of corporate earnings. Oil prices remained elevated near $100 a barrel.
Lilly's $7B Kelonia Buy Targets In Vivo CAR-T Cancer Therapy
Eli Lilly will purchase Kelonia Therapeutics in a deal worth up to $7 billion, gaining an in vivo CAR-T therapy currently in Phase 1 trials for multiple myeloma.
Lilly Acquires Kelonia in $7B Bet on In-Body CAR-T Cancer Therapy
Eli Lilly will purchase Kelonia Therapeutics in a deal valued at up to $7 billion, gaining an experimental in-body CAR-T therapy for blood cancer. Lilly shares rose 2.5% on the news.
Definium's Psychedelic Drug DT120 Gains Analyst Backing Ahead of Key 2026 Data
Definium Therapeutics advanced after Stifel and Piper Sandler issued Buy ratings, spotlighting its LSD-based drug DT120 in late-stage trials for anxiety and depression. The company will host an investor day on April 22 to discuss upcoming Phase 3 data expected through 2026.
Stocks Climb as Oil Retreats, Inflation Data Eases Rate Fears
U.S. equities advanced Tuesday, with the Dow Jones Industrial Average rising approximately 290 points, bolstered by a sharp decline in oil prices and wholesale inflation data that was cooler than anticipated.
Wall Street Rallies on Diplomatic Hopes, Strong Bank Earnings
U.S. stocks advanced sharply Tuesday, with major indexes climbing as hopes for renewed U.S.-Iran talks and a solid start to earnings season lifted market spirits. The Dow gained over 290 points.
J&J Q1 Earnings Surpass Expectations, Lifts 2026 Forecast
Johnson & Johnson exceeded Wall Street's first-quarter forecasts, driven by strong performance from Darzalex and Tremfya. The company raised its full-year 2026 sales guidance.
Eli Lilly Inks $2.75B AI Drug Deal, Posts Positive Trial Data
Eli Lilly has entered a licensing deal with Insilico Medicine potentially worth $2.75 billion and reported strong late-stage clinical results for its immunology and obesity drugs.
Pfizer Shares Dip as GSK RSV Vaccine Gains Ground, Eliquis Data Provides Support
Pfizer shares declined 1% to $26.60 Friday after GSK secured expanded FDA approval for its RSV vaccine, challenging Pfizer's market position. Encouraging clinical results for blood thinner Eliquis helped cushion the drop.
Pfizer Shares Dip Amid Market Selloff, Weight-Loss Drug Approved in China
Pfizer shares declined 1.6% on Thursday, caught in a broad market downturn. The company navigates falling COVID product revenue while advancing its pipeline, including a new weight-loss drug approval in China.
J&J Seeks Earlier Use of Tecvayli in Europe Following US Myeloma Approval
Johnson & Johnson has submitted an application to European regulators to expand the use of its myeloma drug Tecvayli as a monotherapy after just one prior treatment. This follows recent U.S. approval for a Tecvayli combination and is supported by trial data showing a 71% reduction in disease progression risk.
J&J Shares Dip on Lupus Drug Fast Track, Investors Eye Legal Risks
Johnson & Johnson shares declined 0.7% to $245.07 Wednesday after the FDA granted Fast Track designation to its lupus drug candidate nipocalimab, lagging behind a strong market advance.
AbbVie Gains on $8 Billion Bond Sale, Outperforms Slumping Market
AbbVie shares climbed 3.29% to $232.08 on Friday, defying a broader market decline. The pharmaceutical giant is set to raise approximately $7.95 billion through a seven-part bond sale settling March 4.
J&J Shares Dip Amid $20B Orthopedics Unit Sale Talks, New Facility Investment
Johnson & Johnson shares fell following reports the company is exploring a sale of its DePuy Synthes orthopedics business for around $20 billion. The healthcare giant also committed over $1 billion to a new cell-therapy manufacturing plant in Pennsylvania.
J&J Shares Face Post-Holiday Pressure After Latest Talc Verdict
Johnson & Johnson shares closed lower Friday after a jury found the company liable in a baby powder cancer case, awarding $250,000. Investors await Tuesday's trading after the holiday, with the ex-dividend date approaching.
AbbVie Gains Ahead of Holiday; Investors Eye Pipeline and Pricing
AbbVie shares advanced 1.8% to $231.50 in Friday's session, outpacing peers. Trading volume was elevated as investors assess the company's strategic pivot and regulatory challenges.
Healthcare ETF Rises on Dexcom, Moderna Earnings; Markets Eye Holiday
Healthcare stocks advanced Friday, with the XLV ETF rising 1.1% as Dexcom and Moderna posted strong quarterly results. U.S. markets are closed Monday for the Presidents Day holiday.
J&J Stock Dips After $250K Talc Verdict, Eyes on Appeal and Dividend
Johnson & Johnson shares declined 0.45% Friday following a $250,000 verdict in a talc litigation case. The company intends to appeal, with markets closed Monday for the holiday.
Pfizer Shares Dip in Premarket Amid SEC Settlement, Partnership News
Pfizer stock edged lower in premarket trading following a $29 million SEC settlement agreement and a new biotech incubator partnership. Investors await key inflation data.
AbbVie Gains as Analyst Target Hike Meets Macroeconomic Caution
AbbVie shares advanced Tuesday after BNP Paribas Exane raised its price target, while broader markets were mixed as traders awaited delayed U.S. jobs and inflation data.
Boston Scientific Stock Rebounds on Positive Farapulse Data, CHAMPION-AF Trial Looms
Boston Scientific shares recovered slightly after a recent sell-off, supported by new long-term data for its Farapulse ablation system. Investor focus now shifts to the upcoming CHAMPION-AF trial results expected in late March.
JNJ Shares Hold Steady Amid Investor Conferences and Insider Activity
Johnson & Johnson shares traded near $238.70 as the company announced March investor conference appearances and an insider option exercise by Chief Technology & Risk Officer Kathryn Wengel.
Johnson & Johnson Shares Dip in Extended Trading Amid Healthcare Sector Weakness
Johnson & Johnson stock declined 0.6% in after-hours trading Monday as healthcare stocks underperformed the broader market. The company faces ongoing talc litigation and will present at an industry conference next month.
Johnson & Johnson Shares Retreat Amid Healthcare Sector Weakness
Johnson & Johnson stock declined 1.1% as healthcare stocks underperformed the broader market. Traders are eyeing upcoming U.S. jobs and inflation data for direction.
Merck Nears 52-Week Peak Amid Insider Sale, Investors Eye Pipeline Updates
Merck shares climbed 1.8% to $121.93, extending gains for a seventh session and approaching a 52-week high. An executive sold 37,685 shares as investors await the impact of 2026 guidance and pipeline developments.
Johnson & Johnson Stock Nears 52-Week High Amid Legal and Medical Device Updates
Johnson & Johnson shares approached a 52-week high as a New Jersey court disqualified a plaintiffs' firm from talc cases and the company reported positive pilot data for its atrial fibrillation platform.
JNJ Nears 52-Week Peak Amid Legal Win and Promising Heart Device Data
Johnson & Johnson shares approach a 52-week high after a New Jersey court disqualified a plaintiffs' firm from talc cases and the company released positive pilot data for its experimental atrial fibrillation platform.